Latest Vancomycin Stories
The antibiotic linezolid may be more effective than vancomycin in treating ventilated patients who develop methicillin-resistant Staphylococcus aureus (MRSA) pneumonia as a result of their ventilation.
SAN DIEGO, May 12, 2011 /PRNewswire/ -- Optimer Pharmaceuticals (NASDAQ: OPTR) today announced the presentation of an additional analysis of data from the company's two Phase 3 clinical trials of DIFICID(TM) (fidaxomicin), an investigational antibiotic for the treatment of Clostridium difficile Infection (CDI), at the American Geriatric Society (AGS) Annual Meeting held in National Harbor, Maryland. (Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO) The analysis showed that above...
Despite the fact that bedbugs are generally not viewed as a major public health threat, drug-resistant staph bacteria has been found in bedbugs from three hospital patients from a subjugated neighborhood in Vancouver by a team of Canadian scientists.
SEOUL, Korea, May 11, 2011 /PRNewswire/ -- CrystalGenomics, Inc., a biopharmaceutical company with 3 clinical stage candidates, has announced today that the draft Clinical Study Report (CSR) from CG400549's Phase I Multiple Ascending Dose (MAD) Study has just been received. CG400549 is a potential first-in-class antibiotic candidate targeting the fatty acid biosynthesis enzyme FabI, a critical enzyme in generating bacterial membrane and has a novel chemical structure which has never been used...
SAN DIEGO, May 10, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc.
CHICAGO, May 9, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc.
CLEVELAND, May 4, 2011 /PRNewswire/ -- Ganeden Biotech announced today that the company will present new in vivo data on the effect of its GanedenBC30 probiotic strain in C. diff infection at the Digestive Disease Week (DDW) conference in Chicago, Ill., from May 7-10, 2011.
SAN DIEGO, April 28, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc.
EXTON, Pa., April 27, 2011 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that Charles Rowland, vice president and chief financial officer of ViroPharma, will present at the Deutsche Bank 36th Annual Healthcare Conference at 10:40 A.M. ET on Tuesday, May 3, 2011.
EXTON, Pa., April 20, 2011 /PRNewswire/ -- ViroPharma Incorporated's (Nasdaq: VPHM) first quarter financial results for 2011 are expected to be released on Thursday, April 28, 2011 before the open of the U.S.
Enterococcus is a Gram-positive, commensal bacterium inhabiting the gastrointestinal tracts of humans and other mammals. It is a main constituent of some probiotic food supplements. E. faecalis can cause life-threatening infections in humans, especially in the nosocomial environment, where the naturally high levels of antibiotic resistance found in E. faecalis contribute to its pathogenicity. It is frequently found in root canal-treated teeth in prevalence values ranging from 30% to 90% of...
Enterococcus faecalis "“ formerly classified as part of the Group D Streptococcus system "“ is a Gram-positive, commensal bacterium inhabiting the gastrointestinal tracts of humans and other mammals. It is one of the main constituents of some probiotic food supplements. E. faecalis can cause life-threatening infections in humans. It is frequently found in root canal-treated teeth in prevalence values ranging from 30% to 90% of the cases. It is a non-motile, facultatively anaerobic...
- Stoppage; cessation (of labor).
- A standing still or idling (of mills, factories, etc.).